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ABSTRACT 
One of the major limitations to current gene therapy is the low-level and transient vector gene expression due 
to poorly defined mechanisms, possibly including promoter attenuation or extinction. Because the application 
of gene therapy vectors in vivo induces cytokine production through specific or nonspecific i m m u n e responses, 
w e hypothesized that cytokine-mediated signals m a y alter vector gene expression. O u r data indicate that the 
cytokines interferon-y (IFN-y) and tumor necrosis factor-a (TNF-a) inhibit transgene expression from cer-
tain widely used viral promoters/enhancers (cytomegalovirus, Rous sarcoma virus, simian virus 40, Moloney 
murine leukemia virus long terminal repeat) delivered by adenoviral, retroviral or plasmid vectors in vitro. 
A constitutive cellular promoter (/3-actin) is less sensitive to these cytokine effects. Inhibition is at the m R N A 
level and cytokines do not cause vector D N A degradation, inhibit total cellular protein synthesis, or kill in-
fected/transfected cells. Administration of neutralizing anti-IFN-y monoclonal antibody results in enhanced 
transgene expression in vivo. Thus, standard gene therapy vectors in current use m a y be improved by alter-
ing cytokine-responsive regulatory elements. Determination of the mechanisms involved in cytokine-regulated 
vector gene expression m a y improve the understanding of the cellular disposition of vectors for gene trans-
fer and gene therapy. 
OVERVIEW SUMMARY 
Transgene expression can be eliminated even in the pres-
ence of substantial amounts of vector D N A in the trans-
duced cells, which suggests that mechanisms other than the 
antigen-specific immune response may mediate non-cy-
todestructive events that determine the presence of trans-
gene expression. Our data indicate that the cytokines in-
terferon--)/ (IFN-y) and tumor necrosis factor-a (TNF-a) 
inhibit transgene expression from certain widely used viral 
promoters/enhancers (human cytomegalovirus immediate 
early, Rous sarcoma virus long terminal repeat, simian virus 
40, Moloney murine leukemia virus long terminal repeat) 
delivered by adenoviral, retroviral, or plasmid vectors in 
vivo. Inhibition is at the m R N A level and cytokines do not 
cause vector D N A degradation, inhibit total cellular protein 
synthesis, or kill infected/transfected cells. Thus, cytokine-
regulated promoter function rather than specific immune 
destruction could limit transgene expression. These results 
have significant implications for the construction of trans-
fer vectors for human gene therapy because gene transfer 
vectors could be exposed to a cytokine-rich environment 
when they are administered in vivo. 
INTRODUCTION 
GENE THERAPY is a potentially important technique, permit-
ting novel approaches to the tteatment of disease (Crys-
tal, 1995); however, there are limitations due to low-level and 
ttansient gene expression (Friedmann, 1996; Wilson, 1996). 
The use of sttong, constitutive viral promoters does not usually 
achieve long-term ttansgene expression in vivo; and promoter 
extinction occurs (Scharfmann et al., 1991; Challita and Kohn, 
1994; Rettinger et al., 1994), even in the presence of substan-
tial amounts of vector D N A in the transduced cells (Dwarki et 
al., 1995; Yao et al., 1996). Using rettoviral vectors, which in-
tegrate into the host genome and theoretically result in perma-
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nent ttansgene expression, indefinite gene expression is achieved 
in vitro, but only at low levels or not at all in vivo (Scharfmann 
et al, 1991; Rettinger et al, 1994). The immune response to ade-
noviral vectors by cytotoxic T lymphocytes (CTL) is a signifi-
cant limitation to vector expression (Engelhardt et al, 1994; Yang 
et al, 1994; Dai et al, 1995; DeMatteo et al., 1995); and while 
improved transgene expression can be achieved using less im-
munogenic E2 temperature-sensitive adenoviral vectors (Engel-
hardt et al, 1994), immunosuppressants (Yang et al, 1994; Dai 
et al, 1995; DeMatteo et al, 1995; Engelhardt et al, 1994), or 
immunodeficient mice (DeMatteo et al, 1995), expression is ei-
ther not permanent or is still attenuated in comparison to initial 
levels. These findings suggest that other factors are responsible 
for determining ttansferred gene expression. 
It is noteworthy that immune responses may alter ttansgene ex-
pression in other ways. For example, recent studies (Tsui et al, 
1995; Guidotti et al, 1996) demonsttate that in ttansgenic mice 
which replicate the hepatitis B vims (HBV) genome, C D 8 ^ CTLs 
reduce cellular H B V m R N A by a non-cytotoxic mechanism. 
Analysis shows that interferon-y (IFN-y) and tumor necrosis fac-
tor-a (TNF-a), secreted by antigen-activated CTL, result in pro-
moter-specific, post-ttanscriptional clearance of viral mRNA. 
These results suggest that antigen-specific or nonspecific cytokine 
responses initiate a series of inttacellular signals that influence 
transcriptional and ttanslational regulation and hence the level of 
ttansferred gene expression (Gribaudo et al, 1995; Harms and 
Splitter, 1995). W e hypothesize that cytokine-initiated signaling 
is a major determinant of ttansferred gene expression. 
MATERIALS AND METHODS 
Vectors 
Viral and plasmid vectors encoding the LacZ reporter gene are 
shown in Table 1. The adenoviral vectors were all generated from 
adenovims type 5 with an El region deletion. AdHCMV/3-gal 
(Csete et al, 1994), with a human C M V immediate early 1 
(HCMViel) promoter, was provided by Dr. A. Shaked (Univer-
sity of Pennsylvania); AdRSV/S-gal (Sttatford-Perricaudet et al, 
1992) and Ad/3A/3-gal (Grossman et al, 1992), with a Rous sar-
coma vims long terminal repeat (RSV-LTR) and /3-actin promoter 
plus C M V enhancer, respectively, were obtained from the vector 
core of the University of Michigan Medical Center. There may 
be uncharacterized differences other than promoter regions among 
these vectors because they were constmcted by in vivo homolo-
gous recombination in different laboratories. Plasmid vectors: 
pMP6A)3-gal (Philip et al, 1994) with HCMViel promoter was 
provided by Dr. M. Philip (Applied Immune Sciences Inc., Santa 
Clara, CA); pRSV)3-gal (Gorman et al., 1982) with RSV-LTR 
was provided by Dr. G. Warr (Medical University of South Car-
olina); pCHllO (Hall et al, 1983) with SV40 promoter was pur-
chased from Pharmacia (Piscataway, NJ). Rettoviral vector MGF-
LacZ (Tahara et al, 1992) with the Moloney murine leukemia 
vims long terminal repeat (MMLV-LTR) promoter was provided 
by Dr. H. Tahara (University of Pittsburgh). 
Reporter gene expression and cytotoxicity assay 
C2C12 myoblasts (Yaffe and Saxel, 1977) were infected with 
adenoviral vectors at a multiplicity of infection (moi) of 10-100 
for 20 hr (which resulted in > 7 5 % of cells expressing the P-
Gal activity determined by X-Gal staining), or transfected with 
2 p.g of plasmid per 5 X 1 0 ^ cells by 30 /xg of Lipofectamine 
Reagent (GIBCO-BRL, Grand Island, N Y ) in semm-free OPTI-
M E M (GIBCO-BRL) for 5 hr (which resulted 5-10% of cells 
expressing /3-Gal determined by X-Gal staining), or infected 
with a retroviral vector at a moi of 2 in the presence of 8 /xg/ml 
of Polybrene for 20 hr (which resulted in > 5 0 % cells express-
ing /3-Gal determined by X-Gal staining). Cells were then 
trypsinized, replated at 1 X lÔ '-l X 10^ cells/cm̂ , exposed to 
IFN-y and/or TNF-a at various doses for 24—72 hr, and assayed 
for /3-Gal activity, total cellular protein, and cell viability. The 
;S-Gal activity was determined by c>-nittophenyl-/3-D-galac-
topyranoside (ONPG) assay kit (Sttatagene, La Jolla, CA), the 
total cellular protein was determined by Bradford assay (Bio-
Rad, Hercules, CA), cell viability was determined by 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltettazolium bromide (MTT) 
(Sigma, St. Louis, M O ) assay (Mosmann, 1983), cell prolifer-
ation was determined by [^H]thymidine incorporation, and the 
cell cycle was assayed by propidium iodide (PI) (Sigma) assay 
(Noguchi, 1996). All assays samples were performed in tripli-
cate and experiments repeated at least three times. 
Northern and Southern blots 
C2C12 myoblasts were infected with adenoviral vectors and 
treated with cytokines as described above. The cells were lysed, 
and R N A and D N A were isolated separately (Trizol reagent, 
GIBCO-BRL, Grand Island, NY). The R N A was m n on a 1% 
formaldehyde gel and transferred to a nylon membrane (Bio-
Rad, Hercules, CA). The D N A was denatured with 0.2 N N a O H 
and loaded on a nylon membrane. Hybridization was performed 
Table 1. Vectors 
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with [32p]dCTP random primer-labeled probes (Stratagene, La 
Jolla, C A ) specific for /3-Gal, /3-actin, or glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) genes. The /3-Gal probe 
was the 3.7-kb Bam HI-//md III fragment from p C H U O (Hall 
et al, 1983); the ;8-actin probe was a 540-bp polymerase chain 
reaction (PCR) product between base pairs 25 and 565 gener-
ated from C57BL/6 genomic D N A (Alonso et al, 1986); the 
G A P D H probe was a 294-bp reverse ttanscription (RT)-PCR 
product between base pairs 309 and 602 generated from 
C57BL/10J lymphocytes (Sabath et al, 1990). For Southem 
blotting of cardiac allografts, whole transplanted hearts were 
explanted, homogenized in Trizol, D N A isolated, restricted with 
Bam HI, and Southem blotted with [32p]dCTP random primer-
labeled /3-Gal probe for a 4-kb adenoviral fragment. 
Western blot 
Lysates from the tteated cells were mn on a 7.5% SDS-
PAGE, transferred to a nitrocellulose membrane (Bio-Rad, Her-
cules, CA), blotted with a mouse monoclonal antibody (mAb) 
specific for adenovims 72K D N A binding protein (Reich et 
al, 1983), and horseradish peroxidase (HRP)-coupled sheep 
anti-mouse immunoglobulin G (IgG) (Amersham, Arlington 
Heights, IL). The signal was detected by using the E C L West-
em blotting system (Amersham) and exposure to X-ray film. 
P-Ga/ expression in a murine heterotopic, 
nonvascularized cardiac transplantation model 
Donor neonatal C57BL/6 mice (Harlan-Sprague-Dawley, 
Inc., Indianapolis, IN) were sacrificed, and whole hearts were 
removed and placed in a subcutaneous (s.c.) position of the ear 
pinnae of C57BL/6 recipients (Qin et al, 1996) Five X 10'' pfu 
of AdHCMV;8-gal or AdRSV/3-gal in 5 /xl was directly injected 
into the graft at the time of ttansplantation. Anti-IFN-y m A b 
(R4-6A2) (Spitalny and Havell, 1984) and isotype-matched 
conttol m A b Y13-259 (Furth etal, 1982) hybridomas were pur-
chased from the American Type Culmre Collection (ATCC; 
Rockville, M D ) and grown in culture; the culmre supematant 
was purified over protein G columns (Pharmacia-LKB, Piscat-
away, NJ). Purified mAbs were injected intravenously (i.v.) at 
100 /xg every other day for six doses. The ears with ttansplanted 
hearts were harvested at various time points after ttansplanta-
tion, quick frozen, embedded in O.C.T. (Miles Scientific, 
Naperville, IL), sectioned at 10 /xm, collected onto gelatin-
coated glass slides, fixed at room temperature in 0.25% glu-
taraldehyde m phosphate-buffered saline (PBS) for 30 min, 
rinsed three times in PBS for a total of 30 min, and incubated 
at 37°C ovemight m 0.5 mg/ml 5-bromo-4-chloro-3-indolyl-/8-
D-galactopyranoside (X-Gal) solution containing 5 m M potas-
sium ferrocyanide, 5 m M potassium ferricyanide, 2 mAf M g C ^ , 
1 m M spermidine, 0.02% Nonidet P-40, and 0.01% sodium de-
oxycholate in PBS. After staining, the sections were fixed with 
4 % formaldehyde and counterstained with eosin (Qin et al, 
1996). Quantitative assay of inttagraft reporter gene expression 
was performed using the luminescent /3-Gal detection kit II 
(Clontech, Palo Alto, CA) according to the manufacturer's rec-
ommendations. 
RESULTS 
IFN-y and TNF-a inhibit adenoviral vector reporter 
gene expression without killing transduced cells 
To test whether cytokine-mediated signals could alter vec-
tor gene expression, resulting in gene attenuation or extinction, 
C2C12 myoblasts were infected with adenoviral vectors en-
coding the LacZ reporter under the conttol of HCMViel 
(AdHCMV/3-gal), RSV-LTR (AdRSV/3-gal), or /3-actin (Ad-
jSA/3-gal) promoters, exposed to 30 U/ml of IFN-y and/or TNF-
a for 24 hr and assayed for j8-Gal activity, total cellular pro-
tein, cell viability, cell proliferation, and cell cycling. The 
results in Table 2 demonstrate that viral promoters (HCMViel 
and RSV-LTR) were sensitive to the inhibitory effects of the 




















(U/mg of cellular protein) 
21.7 ± 0.6 
16.5 ± 0.4 
9.79 ± 0.29 
6.07 ± 0.13 
2.89 ± 0.05 
1.57 ± 0.08 
1.77 ± 0.09 
0.66 ± 0.26 
5.59 ± 0.41 
4.32 ± 0.20 
6.23 ± 0.74 

















3.95 ± 0.60 
3.86 ± 0.60 
4.13 ± 0.61 
4.14 ± 0.61 
3.94 ± 0.60 
3.78 ± 0.59 
4.06 ± 0.61 
4.00 ± 0.61 
3.93 ± 0.60 
3.96 ± 0.60 
4.00 ± 0.61 













C2C12 myoblasts were infected with indicated adenoviral vectors for 20 hr (which resulted in > 7 5 % of cells expressing the 
/3-Gal activity determined by X-Gal staining), the cells were then exposed to 30 U/ml of IFN-y and/or TNF-a for 24 hr, and 
assayed for j8-Gal activity (expressed as units per m g of cellular protein) and total cellular protein (expressed as m g per 
milliliter of cell lysate from 2 X 10* infected C2C12). The experiment was performed six times with similar results. 
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cytokines, compared to the cellular promoter (/3-actin). There 
was a slight inhibitory effect on the /3-actin promoter by IFN-
y but not by TNF-a. It should be noted that this particular jS-
actin promoter constmct also contained a C M V i e enhancer 
(Grossmann et al, 1992). Nonetheless, it was anticipated that 
a housekeeping gene promoter would be less sensitive to the 
regulatory effects of cytokines. Despite inhibition of /3-Gal ac-
tivity, total cellular protein was unaffected (Table 2), and there 
were no changes in cell viability, proliferation, and cycling (Fig. 
1), showing that the cytokines did not have global inhibitory 
effects on basic cellular functions. Additional experiments 
showed that while IFN-y and T N F - a had inhibitory effects on 
reporter expression, other cytokines, including pro-inflamma-
tory cytokines [interieukin-1 (IL-1), IL-6, and TGF-/3], T H I cy-
tokines (IL-2 and IL-12), T H 2 cytokines (IL-4 and IL-10), and 
chemokines [macrophage inhibitory protein-la (MIP-la), 
M I P 1/3, MIP2, and K C ] did not, even at high doses (not shown). 
IFN-y and TNF-a synergistically inhibit reporter gene 
expression from viral but not cellular promoters 
More detailed dose-response analyses demonsttated that the 
H C M V i e l promoter was sensitive to the inhibitory effects of high 
concenttations of IFN-y and very sensitive to even low doses of 
TNF-a. The R S V - L T R promoter was generally very sensitive to 
IFN-y and less sensitive to T N F - a inhibitory effects. The /3-actin 
promoter showed some sensitivity to only high concenttations of 
either IFN-y or TNF-a (Fig. 2A,B). Whereas the /3-actin and 
H C M V i e l promoters appear to have similar sensitivities to high 
concenttations of IFN-y (Fig. 2A), differences are readily ap-
parent at lower, physiologically relevant concenttations (Table 2; 
Fig. 2C). Importantly, the combination of IFN-y plus T N F - a had 
marked synergistic inhibitory effects on the H C M V i e l and R S V -
L T R promoters, but none did on the /3-actin promoter (Fig. 2C). 
W e conclude that IFN-y and TNF-a initiate marked inhibitory 
and synergistic effects on selected viral promoters (HCMViel, 
R S V - L T R ) but not on a cellular promoter (/3-actin) in adenovi-
ral gene ttansfer vectors. 
IFN-y and TNF-a inhibit transgene expression at 
m R N A level without degrading viral D N A 
To understand the level at which cytokines regulate reporter 
protein expression, Northem blotting was performed on cytokine-
tteated cells and showed that IFN-y plus TNF-a synergistically 
decreased the level of /3-Gal m R N A by about 6 0 % from the 
HCMViel and RSV-LTR promoters, whereas they had much less 
effect on the /3-actin promoter (Fig. 3A). It is interesting to note 
that EFN-y and TNF-a had a similar magnitude of effect on re-
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FIG. 1. IFN-y and TNF-a inhibit reporter gene expression but do not alter cell viability, proliferation and cycling C 2 C 1 2 m v 
oblasts were infected with AdRSV^-gal, tteated with 30 U/ml of the indicated cytokines for 20 hr and assayed for fi Galac 
tosidase activity by O N P G assay (A), cell viability by M T T assay (B), cell proliferation by [^Hlttiymidine incoiporation (C) and 
cell cycle by PI assay (D). "̂  v /. " 
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FIG. 2. IFN-y (A) and TNF-a (B) synergistically inhibit vector gene expression. C2C12 myoblasts were infected with aden-
ovectors encoding the LacZ reporter under the control of HCMViel, RSV-LTR, or /3-actin promoters. After ovemight infection, 
cells were exposed to the indicated cytokines for 48 hr and then assayed for /3-Gal activity by quantitative O N P G assay. Results 
are expressed as percent inhibition of conttol, untteated cultures. C. IFN-y and TNF-a were administered in equal concentra-
tions. The doses shown in the graphs were determined by M T T assay not to be cytotoxic. Higher doses of single or combined 
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FIG. 3. A. IFN-y and TNF-a synergistically inhibit m R N A expression from the H C M V i e l and R S V - L T R but not the /3-actin 
promoter. C2C12 myoblasts were infected with the indicated adenoviral vectors, tteated with 30 U/ml of cytokines for 20 hr, 
R N A was isolated, and Northem blotting was performed for /3-Gal, j3-actin, and G A P D H . Numbers represent the O D ratio of /3-
Gal: G A P D H and percent inhibition of expression. /3-Actin expression showed a pattem identical to G A P D H expression (not 
shown). B. IFN-y and TNF-a affect the expression of adenovirus 72K D N A binding protein. C2C12 myoblasts were infected 
with AdHCMV/8-gal, tteated with cytokines at 30 U/ml for 20 hr, cell lysates m n on 7.5% SDS-PAGE, and Westem blotting 
performed for 7 2 K D N A binding protein. Numbers represent the O D of the protein and percent inhibition of expression. The ex-
periments were performed three times with similar results. 
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(U/mg of cellular protein) 
1.84 ± 0.01 
1.47 ± 0.05 
1.30 ± 0.02 
0.65 ± 0.04 
0.83 ± 0.01 
0.68 ± 0.01 
0.60 ± 0.01 
0.51 ± 0.02 
0.44 ± 0.01 
0.34 ± 0.01 
0.37 ± 0.01 














5 X 1 0 ^ C2C12 cells were ttansfected with 2 p,g of indicated plasmids encoding the LacZ reporter by 30 ;u,g of Lipofectamine 
Reagent (GIBCO-BRL, Grand Island, NY) in semm-free OPTI-MEM (GIBCO-BRL, Grand Island, NY) for 5 hr, treated with 
30 U/ml of IFN-y and/or TNF-a for 24 hr, and assayed as described. The experiment was performed three times with similar 
results. 
hibition in Table 2 versus Fig. 3A). This suggests that m R N A 
ttanscription is a major locus of conttol of gene expression by 
these cytokines. Southem blot analysis of vector D N A from these 
cells showed no difference among the groups (not shown). This 
suggests that IFN-y and TNF-a are not activating cellular mech-
anisms that degrade the vector genome or otherwise rid the cells 
of the vector DNA. Lysates from these same cells were analyzed 
by Westem blotting for the 72K D N A binduig protein of aden-
ovims. The 72K D N A binding protein is normally expressed by 
these El-deleted adenoviral vectors, conttolled by the adenovi-
ral E2 promoter 27 kb downstteam from the reporter, and ttan-
scribed from the linear D N A genome in the opposite direction 
from the reporter gene (Reich et al, 1983). The Westem blot-
ting results (Fig. 3B) demonsttated that IFN-y had no effect on 
72K D N A binding protein expression, whereas TNF-a decreased 
expression by about 30% and the combined IFN-y plus TNF-a 
tteatment decreased expression by about 45%. This shows that 
cytokines may affect not only gene expression conttolled by the 
HCMViel promoter but also expression of other genes on the 
same adenoviral genome. Because the cytokine effects on re-
porter activity and on 72K D N A binding protein expression are 
not the same (compare the percent inhibition in Fig. 3B versus 
Table 2 and the effect of IFN-y versus TNF-a), diis suggests that 
cytokines initiate signals that regulate different viral promoters 
in a promoter-specific fashion. 
IFN-y and TNF-a inhibit transgene expression 
delivered by plasmid and retroviral vectors 
To determine if these cytokine inhibitory effects were asso-
ciated only with adenoviral vectors or could be observed with 
other vectors, C2C12 cells were transfected with plasmid D N A 
encoding the LacZ reporter, or infected with a retroviral vector 
encoding LacZ, treated with IFN-y and/or TNF-a, and assayed 
as described above. The results in Table 3 demonstrate that IFN-
y and TNF-a were able to inhibit plasmid reporter expression 
from HCMViel, RSV-LTR, and SV40 promoters and did so in 
an additive or synergistic fashion. These results are qualitatively 
similM to those with adenoviral vectors, and controls likewise 
showed no effect on cell viability or proliferation (not shown). 
IFN-y and TNF-a also inhibited reporter gene expression from 
tiie retroviral vector MFG-LacZ with the M M L V - L T R pro-
moter (Table 4). Transgene expression could be restored two 
days after these cytokines were removed from culture (Table 
4), which again indicates that inhibition of gene expression is 
at the ttanscriptional and/or ttanslational level and that cy-
tokines do not cause vector nucleic acid degradation or kill 
ttansduced cells. These results further support the hypothesis 
that cytokine-initiated events are acting at the level of ttan-
scriptional control and do not involve other vector or vims-spe-
cific loci or mechanisms. 
Anti-IFN-y mAb prolongs adenoviral vector reporter 
gene expression in vivo 
To determine if cytokine manipulation was also relevant for 
the expression of ttansferred genes in vivo, syngeneic cardiac 
ttansplants were performed using C57BL/6 donor hearts and 
recipient mice. The operative trauma and ischemic injury to the 
graft result in tissue damage and immunologically nonspecific 
generation of cytokines such as IFN-y. The grafts were each 
injected with the viral vector AdHCMV/3-gal. Recipients were 
also untreated or treated with anti-IFN-y m A b or an isotype-
matched control mAb, grafts harvested at various time points 
after ttansplantation, and frozen sections stained with X-Gal for 
^-Gal activity. The treatment with adenoviral vectors or mAbs 
did not affect the survival of tiie syngeneic grafts as determined 
by electtocardiogram (EKG) verification (not shown). The re-
sults in Fig. 4, however, demonsttate that anti-IFN y m A b treat-
ment resulted in more prolonged and higher level /3-Gal ex-
pression, as detennined by X-Gal staining, to at least 30 days 
after transplantation, suggesting enhanced reporter gene ex-
pression as a result of neutralizing IFN-y with specific mAb. 
Similar results were observed using a quantitative /3-Gal as-
say. Reporter gene expression from AdRSV/3-gal could be pro-
longed by anti-IFN-y m A b (Fig. 5) to a level 10 times higher 
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Table 4. Cytokines Inhibit Reporter Gene Expression from a Retroviral Vector 
Cytokines P-Gal activity 
Group (30U/ml) (U/mg of cellular protein) 










1.50 ± 0.02 
0.33 ± 0.03 
1.00 ± 0.08 
0.06 ± 0.03 
1.57 ± 0.01 
0.45 ± 0.02 
0.60 ± 0.01 















1.09 ± 0.01 
0.90 ± 0.01 
1.00 ± 0.02 






2.94 ± 0.10 
2.94 ± 0.40 
2.94 ± 0.44 
2.86 + 0.15 
8.88 ± 1.07 
8.91 ± 1.07 
8.50 ± 1.05 
7.98 ± 1.03 
9.30 ± 1.09 
9.25 ± 1.08 
9.31 ± 1.09 












C2C12 cells were infected with a rettoviral vector MFG-LacZ at moi of 2 in the presence of 8 mg/ml of Polybrene (which 
resulted > 5 0 % cells expressing ;S-Gal determined by X-Gal staining). Transduced cells were treated with 30 U/ml of IFN-y 
and/or TNF-a for (I) 20 hr, (II) 3 days, and (III) 20 hr followed by washing and incubation for an additional 2 days, and assayed 
as described. The experiment was performed three times with similar results. 
than control. These results are commensurate with those ob-
tained with the C2C12 myoblast line in vitro. 
It is possible that these results could be explained not only 
by differences in promoter function as a result of neutralizing 
IFN-y with specific mAb, but also by inhibition of anti-ade-
noviral vector immunity and cytotoxicity by the mAb. To ad-
dress this issue, grafts were harvested 10 days after fransplan-
tation, a time at which there was a large difference in X-Gal 
staining between conttol and treated groups, as shown in Fig. 
4. D N A was isolated, digested with Bam HI, and Southem blot-
ted with the /3-Gal probe. The results demonstrate no difference 
between the groups in the amount of vector D N A in the car-
diac tissues (Fig. 6). This suggests that the difference in reporter 
expression is due to the effects of promoter activity on gene 
transcription and not due to the specific immune response 
killing infected cells, which would have caused a decrease in 
vector D N A and affected syngeneic graft survival, neither of 
which effects were observed. 
D I S C U S S I O N 
The data here indicate that the cytokines IFN-y and TNF-a 
inhibit transgene expression from certain widely used viral pro-
moters (CMV, RSV, SV40, MMLV-LTR) delivered by adeno-
viral, retroviral, or plasmid vectors in vitro. Inhibition is at the 
m R N A level and cytokines do not cause vector D N A degrada-
tion, inhibit total cellular protein synthesis, or kill 
infected/transfected cells. It is possible that these cytokine ef-
fects have not generally been noted previously because most 
Day 5 
Untreated 
Day 10 Day 20 Day 30 
alFNy m A b 
FIG. 4. Anti-IFN-y m A b prolongs adenoviral vector reporter gene expression. Syngeneic cardiac transplants were performed 
and grafts were injected with 5 X 10^ pfu of AdHCMV/3-gal. One group of recipients received no m A b (A-D), while a second 
group was freated with 100 p.g of anti-IFN-y m A b R4-6A2 i.v. on days 0, 2, 4, 6, 8, and 10 with respect to transplantation (E-H). 
Grafts were harvested on days 5 (A and E), 10 (B and F), 20 (C and G), and 30 (D and H) after ttansplantation and stained with 
X-Gal for /3-Gal activity. Original magnification, lOOX. There were at least three grafts for each group at each time point. Groups 
tteated with control Y13-259 m A b were no different from the untreated controls (not shown). 
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Days 
FIG. 5. Anti-lFN-ymAb prolongs adenoviral vector reporter 
gene expression. Syngeneic cardiac transplants were perfonned 
and grafts were injected with 5 x 1 0 ' pfu of AdRSV/3-gal. Re-
cipients were treated with 100 /xg of anti-lFN-y m A b or con-
trol m A b on days 0, 2, 4, 6, 8, and 10 with respect to trans-
plantation. Grafts were harvested 5. 10, 20, and 30 days after 
transplantation and assayed for /3-Gal activity by luminescent 
/3-Gal detection. Note that results are given on a logarithmic 
scale. 
work has been performed in vitro under conditions of low and 
unchanging cytokine concentrations. These results have signif-
icant implications for the constmction of transfer vectors be-
cause there are at least three situations in which gene transfer 
vectors could be exposed to a cytokine-rich environment when 
they are administered ;/; vivo: (i) Gene therapy has been con-
sidered for the treatment of diseases {e.g., cancer, AIDS, trans-
plantation, atherosclerosis, autoimmunity, ischemia-reperfu-
sion) (Crystal, 1995), which have in common the ubiquitous 
production of cytokines through either antigen-specific stimu-
lation of lymphocytes, or nonspecific stimulation of lympho-
cytes, other leukocytes, vascular endothelial cells, or organ 
parenchymal cells by infection, ischemia, necrosis, or trauma. 
(ij) Gene therapy protocols frequently involve gene transfer of 
cytokines to either elicit immune responses (ct;.. cancer) or in-
hibit immune responses (e.g.. transplantation and autoimmu-
nity), (iii) Specific and nonspecific immune responses to gene 
transfer vectors or gene products are capable of inducing sev-
eral cytokines (Engelhardt el «/.. 1994; Yang el al. 1994; Dai 
R 4 6 A 2 YI3-259 
A Wo • • • # • 
FIG. 6. Anti-lFN-y m A b does not affect the persistence of 
adenoviral genomic D N A in cardiac transplants. Recipients of 
syngeneic cardiac grafts infected with 5 X 10^ pfu of 
AdHCMV/3-gal received anti-lFN-y (R4-6A2) or control m A b 
(Y13-259) as detailed in the Materials and Methods section. 
The grafts were explanted after 10 days, and Southem blotting 
for /3-Gal was performed on adenoviral genomic D N A isolated 
from the cardiac tissues. 
et al, 1995; DeMatteo et al, 1995; Krieg el al, 1995; Sato 
et al, 1996). For example, recombinant adenoviruses stimu-
late host immune responses which involve IFN-y and IL-2 
(Engelhardt et al., 1994; Yang et al, 1994; Dai et al, 1995; 
DeMatteo el al, 1995). In addition, the transferred nucleic 
acids themselves are capable of inducing several cytokines in-
cluding IFN-a, 1FN-/3, IL-12, and IFN-y (Krieg et al, 1995; 
Sato et al, 1996). Despite the fact that cytokines are likely to 
be frequently present during gene therapy applications and in-
fluence cellular responses, there are few studies in the current 
gene therapy literature that examine the effects of cytokine 
signals on the transcriptional and translational disposition of 
transferred genes (Harms and Splitter, 1995). Instead, the cel-
lular targets of gene transfer vectors and the other physiologic 
signals impinging on these cells have often been considered 
passive participants in the process of gene transfer and ex-
pr ssion. 
It is notable that the CMVie, RSV, SV40. and M M L V - L T R 
promoters and enhancers, which are cytokine sensitive as shown 
here, are widely used in gene transfer vectors. Thus, vectors in 
current use may not be entirely appropriately constmcted to pro-
vide for sustained gene expression because the cytokine envi-
ronment or the gene transfer product itself may inhibit its own 
promoter. For example, IFN-y and TNF-a have been transduced 
into tumor cell lines or tumor-infiltrating lymphocytes by retro-
viral vectors with the M M L V - L T R promoter (Karp et al, 1993; 
Marincola el al. 1994). Much of the work has focused on char-
acterizing short-term gene expression of cells transduced in 
vitro rather than evaluating chronic gene expression in con-
junction with potential antitumor activity ;>; vivo. In fact, ge-
netically modified, TNF-a-secreting, nonimmunogenic murine 
fibrosarcomas failed to elicit a host immune response, which is 
in contrast to tbe effects with an IL-2-secreting tumor (Karp et 
al, 1993). In other applications of gene therapy, retroviral vec-
tors are used to transduce bone marrow stem cells, which are 
then expanded in the presence of growth factors, such as gran-
ulocyte-macrophage colony-stimulating factor (GM-CSF), 
granulocyte colony-stimulating factor (G-CSF). stem cell fac-
tor (SCF), lL-3, lL-6, and lL-7 (Lu et al. 1993). yet the effects 
of these growth factors on viral promoters or other promoters 
have not been investigated. 
In an attempt to enhance the efficacy of a plasmid D N A vac-
cine to rabies virus, cytokine-expressing plasmids (IFN-y and 
GM-CSF) were co-inoculated with the viral antigen encoding 
plasmid under the control of the SV40 eariy promoter. The G M -
CSF-expressing plasmid increased antiviral immunity by stim-
ulating both the antibody and the T helper cell responses. 
Conversely, an IFN-y-expressing plasmid had no such im-
munostimulatory effects, but rather resulted in a slight decrease 
in antibody and cytokine production (Xiang and Ertl, 1995). 
This unanticipated effect of IFN-y could be due to inhibition 
of the SV4() early promoter by IFN-y, so that less viral antigen 
was produced when the plasmid was co-injected with IFN-y-
expressing plasmid. T lymphocytes are particulariy recalcitrant 
to attempts at stable gene transfer and expression (Rosenberg, 
1991; Chu cl al. 1992). Because these cells are immunologi-
cally active, and in particular produce IFN-y and TNF-a, the 
results presented here may provide a partial explanation for this 
resistance. It should also be noted that these and other cytokines 
can activate these viral promoters under other circumstances 
IFN-y A N D T N F - a INHIBIT V I R A L P R O M O T E R S 2027 
(Tzen and Scott, 1993; Stein et al, 1993; Fietze et al, 1994; 
John et al, 1994 Laegreid et al, 1994); and that these pro-
moters can occasionally direct long-term gene expression in 
vivo, even in immunocompetent recipients (Barr et al, 1995; 
Poller et al, 1996). 
It is well known that IFNs, produced by vims-infected cells 
as part of the innate immune system, can signal to neighboring 
cells to resist viral replication and prevent vims spread (Samuel, 
1991; Farrar and Schreiber, 1993). TNF-a is also a potent an-
tiviral cytokine that acts alone or in a synergistic manner with 
IFN-y to protect cells from viral infection (Wong et al, 1986, 
1992; Wietzerbin et al, 1990). A number of studies suggest 
that these cytokines are basic cellular defenses against viral nu-
cleic acids and that cells can distinguish viral from cellular se-
quences. For example, it has been reported that IFN-y and IFN-
a can inhibit the transcription of murine cytomegalovims 
( M C M V ) immediate-early genes (Gribaudo et al, 1995). The 
inhibitory effect on M C M V i e gene enhancer function is related 
at least partially to cytokine-induced inhibition of NF-/<B ac-
tivity (Gribaudo et al, 1995). It is likely that NF-kB activity is 
directly inhibited by the p202 protein, which is induced by IFN-
y and which direcdy binds to and inhibits the function of the 
p50 and p65 subunits of NF-kB (Wang et al, 1996). p202 can 
also bind to and inhibit the c-fos and c-jun subunits of the AP-
1 ttanscription factor (Wang et al, 1996), which may have neg-
ative regulatory effects because AP-1 binding sites have been 
mapped inside the M C M V promoter/enhancer region (Gribaudo 
et al, 1995). Because p202 inhibits cell cycling and prolifera-
tion, it is probably not mediating the effects observed in the 
present report because the cytokines did not affect C2C12 pro-
liferation. A more recent report shows that IFN-y-induced 
STATl competes for the C B P and p300 co-activator proteins, 
and thereby inhibits AP-1 and ets-dependent transcriptional ac-
tivation (Horvai et al, 1997). There is also recent evidence that 
Kupfer cells, known producers of IFN-y and TNF-a, play a role 
in immunologically nonspecific elimination of adenoviral vec-
tors in the liver following in vivo administtation (Worgall et 
al., 1997). Inhibition of early viral promoters, as shown here, 
provides an additional mechanism for the antiviral effects of 
IFNs and TNF-a. Determination of the mechanisms involved 
in cytokine-regulated gene expression and a comprehensive un-
derstanding of promoter cytokine sensitivities may significantiy 
alter the design of vectors for gene ttansfer and gene therapy. 
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